Altimmune to Participate at the H.C. Wainwright Global Life Sciences Conference

GAITHERSBURG, Md., March 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at H.C. Wainwright Global Life Sciences Conference, being held April 8-10 in Monte Carlo, Monaco.

About AltimmuneAltimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.

Contacts:Bill EnrightPresident and CEOPhone: 240-654-1450[email protected]

Ashley RobinsonLifeSci Advisors, LLC617-535-7742[email protected]

You May Also Be Interested In

• Ant International's Agentic Mobile Protocol Rolls Out Globally with Wallets and Acquirers; Initiating Collaboration on KYA Interoperability Framework with Mastercard and Visa
• Solana Price Prediction: Can SOL Clear $124 After the September 9 Upgrade While Pepeto Fills Its Stage?
• Asia-Pacific Media Tour: Silk Road Culture Market in Eyes of the GBA Wins Global Praise